Cargando…
Characteristic of K3 (CpG-ODN) as a Transcutaneous Vaccine Formulation Adjuvant
Transcutaneous immunization (TCI) is easy to use, minimally invasive, and has excellent efficacy in vaccines against infections. We focused on toll-like receptor (TLR) ligands as applicable adjuvants for transcutaneous formulations and characterized immune responses. TCI was performed using poke-and...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151019/ https://www.ncbi.nlm.nih.gov/pubmed/32183437 http://dx.doi.org/10.3390/pharmaceutics12030267 |
_version_ | 1783521153243938816 |
---|---|
author | Ito, Sayami Hirobe, Sachiko Kawakita, Takuto Saito, Mio Quan, Ying-Shu Kamiyama, Fumio Ishii, Ken J. Nagao, Mizuho Fujisawa, Takao Tachibana, Masashi Okada, Naoki |
author_facet | Ito, Sayami Hirobe, Sachiko Kawakita, Takuto Saito, Mio Quan, Ying-Shu Kamiyama, Fumio Ishii, Ken J. Nagao, Mizuho Fujisawa, Takao Tachibana, Masashi Okada, Naoki |
author_sort | Ito, Sayami |
collection | PubMed |
description | Transcutaneous immunization (TCI) is easy to use, minimally invasive, and has excellent efficacy in vaccines against infections. We focused on toll-like receptor (TLR) ligands as applicable adjuvants for transcutaneous formulations and characterized immune responses. TCI was performed using poke-and-patch methods, in which puncture holes are formed with a polyglycolic acid microneedle on the back skin of mice. Various TLR ligands were applied to the puncture holes and covered with an ovalbumin-loaded hydrophilic gel patch. During the screening process, K3 (CpG-oligonucleotide) successfully produced more antigen-specific antibodies than other TLR ligands and induced T helper (Th) 1-type polarization. Transcutaneously administered K3 was detected in draining lymph nodes and was found to promote B cell activation and differentiation, suggesting a direct transcutaneous adjuvant activity on B cells. Furthermore, a human safety test of K3-loaded self-dissolving microneedles (sdMN) was performed. Although a local skin reaction was observed at the sdMN application site, there was no systemic side reaction. In summary, we report a K3-induced Th1-type immune response that is a promising adjuvant for transcutaneous vaccine formulations using MN and show that K3-loaded sdMN can be safely applied to human skin. |
format | Online Article Text |
id | pubmed-7151019 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-71510192020-04-20 Characteristic of K3 (CpG-ODN) as a Transcutaneous Vaccine Formulation Adjuvant Ito, Sayami Hirobe, Sachiko Kawakita, Takuto Saito, Mio Quan, Ying-Shu Kamiyama, Fumio Ishii, Ken J. Nagao, Mizuho Fujisawa, Takao Tachibana, Masashi Okada, Naoki Pharmaceutics Article Transcutaneous immunization (TCI) is easy to use, minimally invasive, and has excellent efficacy in vaccines against infections. We focused on toll-like receptor (TLR) ligands as applicable adjuvants for transcutaneous formulations and characterized immune responses. TCI was performed using poke-and-patch methods, in which puncture holes are formed with a polyglycolic acid microneedle on the back skin of mice. Various TLR ligands were applied to the puncture holes and covered with an ovalbumin-loaded hydrophilic gel patch. During the screening process, K3 (CpG-oligonucleotide) successfully produced more antigen-specific antibodies than other TLR ligands and induced T helper (Th) 1-type polarization. Transcutaneously administered K3 was detected in draining lymph nodes and was found to promote B cell activation and differentiation, suggesting a direct transcutaneous adjuvant activity on B cells. Furthermore, a human safety test of K3-loaded self-dissolving microneedles (sdMN) was performed. Although a local skin reaction was observed at the sdMN application site, there was no systemic side reaction. In summary, we report a K3-induced Th1-type immune response that is a promising adjuvant for transcutaneous vaccine formulations using MN and show that K3-loaded sdMN can be safely applied to human skin. MDPI 2020-03-15 /pmc/articles/PMC7151019/ /pubmed/32183437 http://dx.doi.org/10.3390/pharmaceutics12030267 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ito, Sayami Hirobe, Sachiko Kawakita, Takuto Saito, Mio Quan, Ying-Shu Kamiyama, Fumio Ishii, Ken J. Nagao, Mizuho Fujisawa, Takao Tachibana, Masashi Okada, Naoki Characteristic of K3 (CpG-ODN) as a Transcutaneous Vaccine Formulation Adjuvant |
title | Characteristic of K3 (CpG-ODN) as a Transcutaneous Vaccine Formulation Adjuvant |
title_full | Characteristic of K3 (CpG-ODN) as a Transcutaneous Vaccine Formulation Adjuvant |
title_fullStr | Characteristic of K3 (CpG-ODN) as a Transcutaneous Vaccine Formulation Adjuvant |
title_full_unstemmed | Characteristic of K3 (CpG-ODN) as a Transcutaneous Vaccine Formulation Adjuvant |
title_short | Characteristic of K3 (CpG-ODN) as a Transcutaneous Vaccine Formulation Adjuvant |
title_sort | characteristic of k3 (cpg-odn) as a transcutaneous vaccine formulation adjuvant |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151019/ https://www.ncbi.nlm.nih.gov/pubmed/32183437 http://dx.doi.org/10.3390/pharmaceutics12030267 |
work_keys_str_mv | AT itosayami characteristicofk3cpgodnasatranscutaneousvaccineformulationadjuvant AT hirobesachiko characteristicofk3cpgodnasatranscutaneousvaccineformulationadjuvant AT kawakitatakuto characteristicofk3cpgodnasatranscutaneousvaccineformulationadjuvant AT saitomio characteristicofk3cpgodnasatranscutaneousvaccineformulationadjuvant AT quanyingshu characteristicofk3cpgodnasatranscutaneousvaccineformulationadjuvant AT kamiyamafumio characteristicofk3cpgodnasatranscutaneousvaccineformulationadjuvant AT ishiikenj characteristicofk3cpgodnasatranscutaneousvaccineformulationadjuvant AT nagaomizuho characteristicofk3cpgodnasatranscutaneousvaccineformulationadjuvant AT fujisawatakao characteristicofk3cpgodnasatranscutaneousvaccineformulationadjuvant AT tachibanamasashi characteristicofk3cpgodnasatranscutaneousvaccineformulationadjuvant AT okadanaoki characteristicofk3cpgodnasatranscutaneousvaccineformulationadjuvant |